<unk>  is an endocrine-metabolic agent that is FDA approved for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.   Common adverse reactions include hypoglycemia, local and systemic hypersensitivity, tonsillar hypertrophy.
Mecasermin
Becaplermin
Palifermin
Dimetan
Metobromuron
Rubitecan
Tioclomarol
Masoprocol